The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Preeclampsia Drugs Market By 2030 Based On Its 2026 Value?
The preeclampsia drugs market has experienced substantial expansion in recent times. Its valuation is projected to rise from $1.37 billion in 2025 to $1.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. Historically, the market’s expansion was influenced by factors such as restricted understanding of preeclampsia management, a dependence on established treatments, an absence of sophisticated monitoring technologies, inadequate hospital facilities, and minimal investment in maternal health pharmaceuticals.
The preeclampsia drugs market size is anticipated to experience substantial growth in the next few years. It is forecast to grow to $2.37 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.8%. The expansion during this period is driven by advancements in drug formulations, the broadening of healthcare infrastructure, increasing demand for outpatient maternal care, the integration of digital health solutions, and enhanced R&D in precision medicine for pregnancy complications. Key trends in the forecast period encompass the rising occurrence of preeclampsia among pregnant women, the creation of novel antihypertensive drugs, a heightened focus on maternal and fetal health monitoring, the growth of hospital pharmacy and specialty clinics as distribution channels, and the use of combination therapies for severe cases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
What Influential Factors Are Boosting The Preeclampsia Drugs Market Demand?
The escalating incidence of diabetes among expectant mothers is anticipated to drive expansion in the preeclampsia drug market. Diabetes, a chronic metabolic disorder, manifests through elevated blood glucose levels. Preeclampsia, on the other hand, is a severe pregnancy complication marked by high blood pressure and damage to organs. Metformin, a medication for preeclampsia, sees extensive application in pregnant women facing preterm preeclampsia. Illustratively, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, more than half a million (549,000) new individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total count of individuals with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP, to 3,615,330. This figure signifies a substantial increase when compared to 3,065,825 in 2022, indicating a growth of nearly 20%. Consequently, the growing prevalence of diabetes in pregnant women will fuel the preeclampsia drug market.
What Segment Categories Are Evaluated In The Preeclampsia Drugs Market Study?
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy
What Trends Are Influencing The Preeclampsia Drugs Market?
Leading companies in the preeclampsia medicine market are concentrating on developing advanced therapies, such as small interfering RNA (siRNA) treatments, to address significant unmet medical needs with novel mechanisms of action. Investigational siRNA therapies represent a class of medicines engineered to silence or turn off specific genes responsible for causing a disease, providing a targeted approach to treatment. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, announced that the Food and Drug Administration (FDA) had approved an investigational new drug (IND) application for CBP-4888, Comanche’s unique siRNA treatment for preeclampsia. CBP-4888 is a subcutaneously administered siRNA therapy that reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The primary cause of preeclampsia is the placenta’s overproduction of the protein sFLT1, which then enters the mother’s circulation. CBP-4888 has the potential to alleviate preeclampsia symptoms, such as high blood pressure and organ damage, and may allow for the safe extension of pregnancy.
Who Are The Firms Contributing To The Preeclampsia Drugs Market Ecosystem?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp
Access The Complete Preeclampsia Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Which Region Is The Primary Market For The Preeclampsia Drugs Market?
North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Preeclampsia Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2026, By The Business Research Company
Preeclampsia Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Fertility Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report
Epilepsy Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model